AIM
RUBY

ARK Investment Management’s Rubius Therapeutics, Inc RUBY Stock Holding History

ARK Investment Management’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-318,121
Closed -$1.42M – 217
2020
Q1 		$1.42M Sell
318,121
-362,643
-53% -$2.69M 0.04% 99
2019
Q4 		$6.47M Sell
680,764
-50,126
-7% -$485K 0.16% 70
2019
Q3 		$5.74M Buy
730,890
+32,488
+5% +$379K 0.13% 69
2019
Q2 		$11M Buy
698,402
+168,787
+32% +$2.72M 0.28% 51
2019
Q1 		$9.59M Buy
529,615
+214,463
+68% +$3.29M 0.27% 50
2018
Q4 		$5.07M Buy
315,152
+126,884
+67% +$2.31M 0.21% 61
2018
Q3 		$4.52M Buy
+188,268
New +$4.3M 0.14% 72

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

ARK Investment Management's RUBY Position: Q2 2020 in Review

ARK Investment Management sold out of Rubius Therapeutics, Inc (RUBY) in Q2 2020, closing a stake of 318,121 shares — an estimated $1.42M sold.

ARK Investment Management first reported a position in RUBY in Q3 2018 and held it in 7 quarters. The position peaked at $11M in Q2 2019. 86 funds tracked by Wall St. Rank hold RUBY as of Q2 2020.

  • ARK Investment Management reported no remaining Rubius Therapeutics, Inc position as of Q2 2020 after selling out during the quarter.
  • ARK Investment Management sold 318,121 Rubius Therapeutics, Inc shares in Q2 2020, an estimated $1.42M.
  • ARK Investment Management first reported a position in Rubius Therapeutics, Inc in Q3 2018 and held it in 7 quarters.
  • ARK Investment Management's Rubius Therapeutics, Inc position peaked at $11M in Q2 2019.
  • 86 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q2 2020.

Based on ARK Investment Management's 13F filing for Q2 2020, filed 11 Aug 2020.